Previous Close | 0.7400 |
Open | 0.7300 |
Bid | 0.7836 x 2200 |
Ask | 0.7944 x 1300 |
Day's Range | 0.7300 - 0.7994 |
52 Week Range | 0.6790 - 5.9500 |
Volume | |
Avg. Volume | 1,228,916 |
Market Cap | 32.339M |
Beta (5Y Monthly) | 2.69 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.2400 |
Earnings Date | May 13, 2024 - May 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.75 |
Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The latest analyst coverage could presage a bad day for Spruce Biosciences, Inc. ( NASDAQ:SPRB ), with the analysts...
Spruce Biosciences' (SPRB) CAHmelia-203 phase IIb study of tildacerfont in adult patients with CAH fails to meet the primary efficacy endpoint.